LEADER (trial)

LEADER is the trial that turned GLP-1 drugs from blood-sugar medicines into cardiovascular ones. It enrolled 9,340 adults with type 2 diabetes who were either already living with cardiovascular disease or at high risk of it, and randomized them to daily liraglutide or placebo on top of standard care. Median follow-up was 3.8 years. Marso and colleagues published it in the New England Journal of Medicine in 2016.

The primary outcome was the three-part composite clinicians call MACE: death from cardiovascular causes, a nonfatal heart attack, or a nonfatal stroke. It happened in 13.0% of the liraglutide group (608 of 4,668) versus 14.9% on placebo (694 of 4,672) — a hazard ratio of 0.87, statistically significant for superiority. Cardiovascular death alone fell from 6.0% to 4.7%, and death from any cause from 9.6% to 8.2%.

Read that carefully, because the way benefits get reported causes real confusion. “A 13% relative risk reduction” and “1.9 fewer events per 100 people over about four years” describe the same finding. The relative number sounds bigger; the absolute number is what tells you how likely you personally are to benefit. Both are honest, and a good conversation with a clinician uses both.

LEADER matters historically because it came first. SUSTAIN-6 reported semaglutide’s cardiovascular results later the same year, REWIND followed for dulaglutide, and SELECT eventually extended the finding to people with obesity but no diabetes. Not every GLP-1 replicated it — EXSCEL and ELIXA were neutral — which is why the class is not treated as interchangeable for heart protection.

Worth asking your clinician: whether your cardiovascular risk is high enough that this evidence should influence which drug you take, and whether the specific product you are prescribed carries a cardiovascular indication on its label. Our cardiovascular study roundup compares them side by side.